Previous 10 | Next 10 |
home / stock / xphy:cc / xphy:cc news
VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / June 27, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) ("XPhyto" or the "Company") is pleased to congratulate Prof. Dr. Raimar Loebenberg as the 2022 recipient of the CSPS Award of Leadership in Canadian Pharmaceutic...
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced that Dr. Florian A. Sahr has joined its European operations as head of project management. A German-born and internationally trained leader in formulation, technology transfer and new-product manufacturing, Dr. Sahr ...
VANCOUVER, BC and UTTENWEILER / ACCESSWIRE / June 8, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to report that Dr. Florian A. Sahr has joined its European operations as Head of Project Management. Dr. Sahr is a German-born and...
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience accelerator at the leading-edge of the life science industry, has released an update on its Rotigotine transdermal ("TDS") patch. The patch is based on the TDS platform technology developed by the company’s...
VANCOUVER, BC, AND UTTENWEILER, GERMANY / ACCESSWIRE / May 9, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide a product development report on its Rotigotine transdermal ("TDS") patch, including results of its recent human ...
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has released a market and product development report. The report focused on XPhyto’s sublingual oral dissolvable film ("ODF") biosensor developm...
VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / April 11, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide a market and product development report on its Sublingual oral dissolvable film ("ODF") biosensor development ...
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience accelerator at the leading-edge of the life science industry, is reporting on the market and product development of its Rotigotine transdermal ("TDS") patch, which is designed for the treatment of Parkinson's dise...
VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / April 4, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) ("XPhyto" or the "Company") is pleased to provide a market and product development report on its Rotigotine transdermal ("TDS") patch. The Company's Rotigotine...
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has announced that, further to its news release of March 25, 2022, it has closed the f...
News, Short Squeeze, Breakout and More Instantly...
Xphyto Therapeutics Corp. - Common Shares Company Name:
XPHY:CC Stock Symbol:
CNQC Market:
Toronto, Ontario--(Newsfile Corp. - Le 10 novembre/November 2022) - XPhyto Therapeutics Corp. (XPHY) has announced a name and symbol change to BioNxt Solutions Inc. (BNXT). Shares will begin trading under the new name and symbol and with a new CUSIP number on November 14, 2022. Disclos...
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) has announced a name change. According to the company, effective next Monday, Nov. 14, 2022, the company’s name will change from XPhyto Therapeutics Corp. to BioNxt Solutions Inc. Along with the name change, the com...
VANCOUVER, BC / ACCESSWIRE / November 10, 2022 / XPhyto Therapeutics Corp. (" XPhyto " or the " Company ") (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce that effective November 14, 2022, the Company's name will change from "XPhyto Therapeutics Corp." to " BioNxt Solutions Inc. ". A...